Ianalumab Results Show Modest Impact in Sjögren's Trials
The drug shows potential for improving disease activity scores, but does not currently improve dryness in these patients.
Updated on Oct. 21, 2026 in Diabetes
Live Poll
Do you trust that pharmaceutical companies prioritize clear proof of clinical benefit in new drug trials?
Researchers recently published phase III clinical trial results for the drug ianalumab in patients with Sjögren's disease. While the treatment met its primary endpoint, it showed no significant difference from placebo in secondary clinical symptoms.
Why it matters
Sjögren's disease is a complex autoimmune condition, and these results help clarify the potential effectiveness of B-cell activating factor inhibitors. Patients and doctors should note that while disease activity scores improved, relief from specific symptoms like dryness remains unproven.
The results come from two randomized phase III trials involving 779 patients with Sjögren's disease. While the drug showed a statistically significant improvement in ESSDAI scores versus placebo, secondary outcomes including salivation and dryness showed no significant difference.
The players
Novartis
A global pharmaceutical company focused on innovative medicines for immune, cardiovascular, and oncological diseases.
The details
Ianalumab works by inhibiting the B-cell activating factor, a protein involved in the development and survival of B-cells that may contribute to autoimmune activity in Sjögren's disease. Participants received the drug via monthly injections to measure changes from baseline. The trials also tested a 3-month dosing schedule, which failed to show a difference compared to placebo.
Timeline
May 2026: The THALASSA trial was first listed.
Q3 2026: Target window for Novartis marketing applications.
August 2029: Estimated primary completion of the THALASSA trial.
Health Landscape
The development of B-cell activating factor inhibitors represents a significant shift in targeting the underlying autoimmune drivers of Sjögren's disease. These findings represent a transition from theoretical models to large-scale phase III data testing the limits of these therapies.
These findings are strictly for clinical research purposes and do not represent a new treatment option for patients. Discuss these results with your physician to understand how they may impact future treatment landscape expectations.
The takeaway
These study results demonstrate that while ianalumab affects disease activity scores, it did not significantly impact patient-reported symptoms like dryness. Patients should continue working with their rheumatologists to manage Sjögren's disease using established therapies.
What happens next
The THALASSA trial is currently recruiting with an estimated primary completion date of August 2029.
Further reading
Learn more about the latest research and standard of care in the Diabetes section.
Source note: This article includes information reported by MedPage Today.
Live Poll
Do you trust that pharmaceutical companies prioritize clear proof of clinical benefit in new drug trials?
